Conexeu investor reports 9.99% passive stake
An institutional investor reports beneficial ownership of up to 9.99% of Conexeu Sciences Inc. common shares, including warrant holdings subject to an ownership cap.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Conexeu Sciences Inc. (CNXU) has a significant shareholder reported on a Schedule 13G. Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund is disclosed as beneficially owning 4,400,305 common shares, including 2,200,000 common share warrants. The filing states this represents ownership of up to 9.99% of the outstanding common shares. The fund reports sole voting and dispositive power over all of these securities, subject to a 9.99% beneficial ownership limitation that restricts warrant exercises above that level.
Key Figures
Key Terms
beneficially owned financial
dispositive power financial
warrants financial
Percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Conexeu Sciences Inc. (CNXU) does this 13G report?
How many CNXU warrants are included in the reported beneficial ownership?
Who signed the Schedule 13G for Conexeu Sciences Inc.?
AI-generated analysis. How Rhea-AI works. Not financial advice.